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We read with great interest the study by van Maaren et al. 
recently published in Lancet Oncology (1). This study, 
conducted on a large Dutch population, shows that breast 
conservative surgery (BCS) associated with radiotherapy 
is at least comparable in terms of overall survival to 
mastectomy. Interestingly, in the subgroup of patients with 
early stage disease thus with lower prognostic risk (pT1N0), 
the study reports that mastectomy is even detrimental on 
survival compared to BCS combined with radiotherapy. 
Apparently, the lack of exposure to radiation therapy in 
patients who underwent mastectomy could explain the 
unfavorable prognostic impact. Although, paradoxically, the 
benefit of radiation treatment is lost in the subgroups with 
worst prognosis stage (pT2N0, pT1-2N1), in which the 
impact of such treatment is expected to be superior. The 
Authors defend these results in the light of the statistical 
significance of these data in the multivariate analysis, which 
includes various factors that may influence the prognosis.
However, in the absence of a biological rationale and 
given the data inconsistency in respect to the evidences of 
randomized prospective studies (2-4), we believe that these 
results may arise from both population selection bias and 
the lack of essential biological prognostic factors in the 
multivariate analysis.
Among the selection bias, partially discussed by the 
Authors, it is evident that the patients enrolled in the 
mastectomy arm were significantly older. This was to be 
expected since mastectomy is indicated in small breast 
tumor in order to limit the exposure to radiation therapy 
in patients with reduced compliance such as older people. 
About 14% of patients in the mastectomy arm were over 
79 years old compared to 2% in the BCS arm. Although the 
Authors claim to have corrected this selection bias in the 
multivariate analysis, the age cut-off used for the statistical 
analysis is not clearly specified. The age cut-off selected 
could significantly impact on the final statistical result.
Another bias that could explain the unexpected outcome 
observed by van Maaren et al. is the absence of stratification 
for breast cancer biological prognostic factors such as 
ER, PgR and HER-2 expression and Ki 67 levels. These 
prognostic factors, despite the limitations connected with 
their immunohistochemical determination, are routinely 
used in everyday clinical practice to quantify the risk of 
recurrence and survival of breast cancers. In spite of this, 
about 60% of the population in both groups did not have a 
valid detection of hormone receptors (ER and PgR) and no 
patient had HER-2 and Ki 67% determination. Nowadays 
genetic signatures, mainly based on the expression of these 
proteins (5) are prospectively validated to significantly 
impact on breast cancer prognosis. This impact on 
prognosis appears to be greater especially in small size 
cancers without lymph node involvement, in which the risk 
of recurrence is mainly influenced by the metastatic tropism 
secondary to the genetic and molecular profile of the disease 
rather than by the stage of the disease.
Thus, an imbalance between the two groups in these 
factors may determine the incomprehensible detrimental 
effect of mastectomy in early stage (pT1N0) patients, which 
is lost in the subgroups of patients with advanced cancer 
(pT2N0, pT1-2N1) where the disease stage impacts more 
on survival.
Given these considerations, this large population study 
allows exclusively to confirm in real-world that BCS 
plus radiotherapy and mastectomy are equally effective. 
Whereas, we believe that in the age of precision medicine 
the results from the subgroup analysis (pT1N0), in the 
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absence of biomolecular data, cannot change clinical 
practice limiting the mastectomy, which currently remains a 
viable option in selected patients with small tumors.
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